MORF-720 / AbbVie, Eli Lilly - LARVOL DELTA

Morphic Announces that AbbVie Exercises License Option to αvβ6 Integrin Inhibitor Program, Including MORF-720, for Fibrotic Diseases (GlobeNewswire) - "Morphic Therapeutic...and AbbVie...today announced that AbbVie has exercised a license option under the companies’ research and development collaboration agreement to develop Morphic’s αvβ6 integrin inhibitors for the treatment of fibrotic diseases including idiopathic pulmonary fibrosis (IPF) and additional indications....The license covers αvβ6 integrin specific inhibitors discovered from Morphic’s proprietary MInT Platform, including the compounds MORF-720...Morphic will receive a license fee of $20 million, with potential future development milestone payments and royalties from the sales of any commercialized candidates."

Licensing / partnership • Idiopathic Pulmonary Fibrosis